M-01: Efficacy and Safety of Tyrosine-Kinase Inhibitors as First-Line Treatment in Advanced NSCLC Patients: A Network Meta-Analysis
Poster Presenter
Ismaeel Yunusa
Graduate Student
Massachusetts College of Pharmacy and Health Sciences United States
Objectives
To compare the efficacy and safety of EGFR-TKI’s as first-line treatment in patients with locally advanced, metastatic NSCLC with positive EGFR mutation.
Method
We searched the following databases; PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for relevant articles up to December 2018. We selected RCTs comparing at least 2 TKIs or a TKI with PBCT. We performed a frequentist random-effects NMA using the multivariate meta-analysis approach.
Results
Fifteen eligible trials (3750 patients) were included. There were statistically significant differences between some TKIs and PBCT for overall survival (OS), progression-free survival (PFS) and grade 3 or higher adverse events. PFS results suggests that dacomitinib had highest probability of being the most effective (SUCRA, 75.9%), followed by, osimertinib (SUCRA, 69.5%), erlotinib (SUCRA, 59.9%), afatinib (SUCRA, 55.9%), gefitinib (SUCRA, 36.1%), PBCT (SUCRA, 2.7%). We observed a similar ranking trend for OS except for the fact that dacomitinib and osimertinib has no OS data. Adverse events results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA, 78.9%) has the highest probability of being the safest. Upon simultaneously visualizing efficacy and safety in cluster plots, osimertinib, gefitinib, and erlotinib formed a cluster for the most effective and safe TKIs while dacomitinib and afatinib formed a cluster for lesser safety and effective TKIs.
Conclusion
This NMA suggests that osimertinib, gefitinib, and erlotinib might be the most efficacious and safest TKIs.
This website uses cookies. Click accept cookies to continue. Or you can disable cookies, but it will affect your experience. Learn more.